BioSpace News Archive

Helius Medical Technologies, Inc., a neurotech company focused on neurological wellness, announced a partnership with Breakthrough Health, a Berlin-based technology company.

Showedsignificant improvements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases

OpSens Inc., a medical device cardiology-focused company commercializing a second-generation fiber optic pressure guidewire to diagnose and treat coronary disease, announced it has been awarded a 3-year contract by a major American Group Purchasing Organization.

In an unrelated development, apartnerinitiated Phase 2 development of an undisclosed asset, which triggers $0.5 million milestone payment to XOMA

Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it will report results for the third quarter ended September 30, 2020 and provide a business update after market close on Wednesday, November 4, 2020. Management will host a conference call for investors at 8:00 a.m. ET on T

NeuroPharm, Inc. (“NeuroPharm”), a wholly-owned subsidiary of Mydecine Innovations Group, Inc., (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) announced today it has engaged FreeMind Group LLC to assist NeuroPharm in securing non-dilutive funding opportunities globally. NeuroPharm™ is developing a unique and proprietary set of pharmaceutical and natural health products addressing mental wellness in vulnerable populations including Veterans

Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) announced today that Vision Leader Limited, a wholly-owned subsidiary of ORI Star Fund LP (“ORI”), has delivered a notice of conversion to convert its entire September 2019 debenture and associated interest, into Resverlogix common shares, which will discharge all security interests associated with the debenture. The US$12 million (approximately CAD$15.8 million) principal amount of the debe

Moberg Pharma AB announced its decision to request pre-submission meetings with regulatory agencies, with the goal of submitting a registration application in the second half of 2021 in Europe.

License agreement provides Rentschler Biopharma full access to ATUM’s Leap-In Transposase® cell line development (CLD) tools

Nimbus Therapeutics, a biotechnology company designing breakthrough medicines through structure-based drug discovery and development, announced the close of a $60 million private financing round from life science investors RA Capital Management and BVF Partners L.P.